公司資料
Pulmatrix 股價、新聞與催化劑
- 股票代碼:
- PULM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.56 USD (+1.30%)
收盤價
最後更新: 2026年8月17日
4.82M USD
市值
股價為何變動
As of Aug 17, 2026, PULM closed up 1.30% at $1.56. No new same-company headline was identified in the current news window.
公司概覽
Inhaled Drug-Delivery Company
Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX.
iSPERSE Technology
iSPERSE creates small, dense, dispersible particles intended to improve pulmonary drug delivery compared with conventional dry powders.
PUR1900
PUR1900 is an inhaled formulation of itraconazole for fungal lung disease. Partner Cipla controls continued development in India.
PUR3100 and PUR1800
PUR3100 is a Phase 2-ready inhaled dihydroergotamine program for acute migraine, while PUR1800 is an inhaled kinase inhibitor previously studied in chronic obstructive pulmonary disease.
未來催化劑
- Initiation of the Cipla-led Phase 3 study of PUR1900 in India in 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。